Local IGF-I expression and bone formation

Growth Hormone and IGF Research

Volumn 11, Issue 4, 2001, Pages 213-219

  McCarthy, Thomas L ^a   Centrella, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C EBP; Glucocorticoid; IGF I; Oestrogen; Osteoblast; PGE2; PTH; Run x2

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; DEXAMETHASONE; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; PARATHYROID HORMONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STEROID HORMONE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE REMODELING; DRUG HALF LIFE; DRUG MECHANISM; ESTROGEN THERAPY; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0035186731     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.2001.0236     Document Type: Review

References (53)

1. A personal view on the early history of the insulin-like growth factors(1)
2. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5
3. The importance of growth hormone replacement therapy for bone mass in young adults with growth hormone deficiency
4. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome
5. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study
6. Gender difference in growth hormone response in adults
7. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: A 5-year study
8. Mice carrying null mutations of the genes encoding insulin-like growth factor I (lgf-1) and type 1 IGF receptor (lgf1r)
9. Inactivation of the IGF-I gene in mice results in perinatal lethality
10. Insulin like growth factor I (IGF-I) is required for the anabolic actions of parathyroid hormone (PTH) on bone
11. Anabolic actions of PTH in vivo are IGF-I dependent: Studies using IGF-I knockout mice
12. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
13. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication
14. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures
15. Potential role of rhIGF-I/IGFBP-3 in maintaining skeletal mass in space
16. Insulin-like growth factor-I supports formation and activation of osteoclasts
17. Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: An in vitro study
18. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I
19. Dietary protein restriction lowers plasma insulin-like growth factor I (IGF-I), impairs cortical bone formation and induces osteoblastic resistance to IGF-I in adult female rats
20. IGFs and human cancer: Implications regarding the risk of growth hormone therapy
21. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast enriched cultures from fetal rat bone
22. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures
23. Isolation and characterization of insulin-like growth factor I (somatomedin-C) from cultures of fetal rat calvariae
24. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption
25. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: Histomorphometric evidence in a longitudinal study
26. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial
27. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration
28. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
29. The parathyroid hormone, its fragments and analogues-potent bone-builders for treating osteoporosis
30. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats
31. Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone
32. Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures
33. Regulation of insulin-like growth factor I transcription by cyclic adenosine 3′,5′-monophosphate (cAMP) in fetal rat bone cells through an element within exon 1: Protein kinase A-dependent control without a response element
34. The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts
35. The response of bone to unloading
36. Osteocytic expression of mRNA for c-fos and IGF-I: An immediate early gene response to an osteogenic stimulus
37. The role of prostaglandins and nitric oxide in the response of bone to mechanical forces
38. Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: Evidence for transcriptional control
39. Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E2 in osteoblasts
40. Biological role of the CCAAT/enhancer-binding protein family of transcription factors
41. CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone
42. Runt domain factor (Runx)-dependent effects on CCAAT/enhancer-binding protein delta expression and activity in osteoblasts
43. Regulated nuclear-cytoplasmic localization of CCAAT/enhancer-binding protein delta in osteoblasts
44. Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells
45. Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3′,5′-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts
46. Epidemiology and pathogenesis of osteoporosis
47. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
48. Estrogen receptor gene disruption: Molecular characterization and experimental and clinical phenotypes
49. Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model
50. 17 Beta-estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures
51. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family
52. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat
53. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women